We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Elixirr International Plc | ELIX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -11.00 | -1.65% | 655.00 | 09:38:59 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 665.00 | 655.00 | 674.00 | 666.00 |
| Industry Sector |
|---|
| SUPPORT SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 28/04/2025 | Final | GBP | 0.115 | 24/07/2025 | 25/07/2025 | 20/08/2025 |
| 20/12/2024 | Interim | GBP | 0.063 | 23/01/2025 | 24/01/2025 | 17/02/2025 |
| 22/04/2024 | Final | GBP | 0.095 | 25/07/2024 | 26/07/2024 | 20/08/2024 |
| 08/01/2024 | Interim | GBP | 0.053 | 18/01/2024 | 19/01/2024 | 15/02/2024 |
| 27/02/2023 | Final | GBP | 0.108 | 20/07/2023 | 21/07/2023 | 18/08/2023 |
| 04/04/2022 | Final | GBP | 0.041 | 14/07/2022 | 15/07/2022 | 12/08/2022 |
| 12/04/2021 | Final | GBP | 0.022 | 15/07/2021 | 16/07/2021 | 13/08/2021 |
| Top Posts |
|---|
Posted at 18/6/2025 17:26 by eagle eye hazl,I've been an investor in ELIX over several years and find the share price tracks up and down with irritating regularity. Easy to bail out after weakness then chase the price up after a positive RNS. The company lays out it's stall in many of it's Investor Meet Company presentations and when I met management at last year's AGM I got the impression the team is both capable and ambitious. Finding companies that are worth backing is one thing. Managing the space between the ears and to get entry/exit timing right is another matter. |
Posted at 18/6/2025 12:38 by eagle eye ELIX share price likely to remain weak prior to full listing as IHT funds unload holdings.ELIX says it's looking to join FTSE 250 at some stage, so index trackers will then be buyers. |
Posted at 18/6/2025 09:18 by hazl And dividend not to be sniffed at.Main market gives it more credibility, too. IMO |
Posted at 28/4/2025 13:30 by martinmc123 wealthoracle.co.uk/d |
Posted at 03/4/2025 10:58 by masurenguy The price slide today is just part of the general market negative sentiment following Trump's ridiculous tarrif nonsense. We don't know how long this will last but in the meantime it is worth pointing out that circa 40% of ELIX business is in the USA. However this is conducted by American partners who live there and is not impacted by any tarrifs. In fact this might boost their business going forward as some of their clients seek ways of minimizing the impact of the retaliatory tarrifs that will be applied to US products in due course by countries where they have export customers. |
Posted at 03/4/2025 09:25 by 74tom Today's further fall reminds me of the spike down to 420p in November 2023, by Christmas 2023 they were back to 600p. That low had shares valued at ~11.5x 2024 forecast earnings, whereas at today's 630p ELIX is valued at ~13x 2025 forecast earnings, vs the ~18x it traded it in the 2 weeks after the latest trading update.What makes me laugh about selloffs like this is the number of small retail holders who chase the bid down. If you didn't sell you 365 shares at 860p a month ago why would you sell them today at 620.3p? Will be very surprised if shares aren't trading well above £7 on 28th April when they release results. |
Posted at 01/4/2025 08:43 by tightfist Worth re-reading the 2024 TU on 18 Feb - since then ELIX has fallen 18% - figure that out! |
Posted at 20/12/2024 07:54 by masurenguy Interim Dividend for the Year Ending 31 December 2024In accordance with the Company's dividend policy announced on 8 January 2024, the Company will continue to declare 2 dividends per year, with an interim dividend paid after the end of the year and a final dividend payable in August. The Company is declaring an interim dividend of 6.3p per Ordinary Share. The Dividend will be payable to Shareholders on the register as at 24 January 2025 and has an associated ex-dividend date of 23 January 2025. The Dividend of approximately £3.0m in total will be paid to Shareholders on 17 February 2025, funded from the Company's operating cash flow. |
Posted at 08/1/2024 07:16 by masurenguy Trading Update, Change to Dividend Policy and Interim DividendElixirr International plc is pleased to provide an update on trading in the year ended 31 December 2023 ("FY23"), advise shareholders of a change in dividend policy and announce an interim dividend. Trading Subject to audit, FY23 results are expected to be in line with market expectations with: - Revenue within the guidance range of £85m - £90m - Adjusted EBITDA of approximately £25.4m - Year-end cash of approximately £17.9m Dividend Policy In line with comparable companies, the Board has decided to declare two dividends per year, with an interim dividend payable shortly after the end of the year and a final dividend payable in August. Interim Dividend The Company is declaring an interim dividend (the "Dividend") of 5.3p per Ordinary Share. The Dividend will be payable to Shareholders on the register at 19 January 2024 and has an ex-dividend date of 18 January 2024. The Dividend of approximately £2.5m in total will be paid to Shareholders on 15 February 2024 and funded from the Company's existing cash reserves. |
Posted at 06/11/2023 11:41 by simon gordon On the iOLAP website they have twenty vacancies, business must be strong.Thought this a decent summary: Investors Chronicle - 7/9/23 A capital-light consultancy with excellent momentum Boutique consultancies do not often crop up on the public market. Pay attention when they do. by Jemma Slingo “The concept of a structured work-life balance almost seems to be expected in today’s society – especially in a typical 9-to-5 role, but I think it should be seen as a privilege.” So says Stephen Newton, founder and chief executive of Elixirr (ELIX), a management consultancy that joined Aim three years ago. It’s a fitting message from an entrepreneur set on driving growth and trimming the fat. Elixirr presents itself as a new breed of management consultancy. It used a recent ad campaign to lampoon the industry’s jargon, swagger and reliance on under-experienced Oxbridge graduates, and continually stresses its “challenger&rd Punching above its weight With a market cap of under £250mn, Elixirr is small – even compared with specialist listed consulting peers such as Alpha Financial Markets Consulting (AFM) and XPS Pensions (XPS). However, it benefits from a similarly capital-light business model and excellent momentum. Indeed, according to Investec, Elixirr is the fastest-growing management consultancy in the UK and the third-fastest in Europe. Having increased its market share every year since 2011 and posted organic revenue growth of 18 per cent in 2022, Elixirr has momentum. With an adjusted Ebitda (earnings before interest, tax, depreciation and amortisation) margin at around 30 per cent, it is also profitable. The company was founded in the aftermath of the financial crash, and originally focused on financial services work, which is Newton’s area of expertise. Around half of group turnover still comes from the sector, but Elixirr is rapidly diversifying, and its 200-strong client base now includes names as varied and big-ticket as Diageo, LVMH, Tesla and Burger King. The fact that big names are on board suggests this youthful small cap is an increasingly viable alternative to the ‘Big Four’ professional services firms and strategy houses such as McKinsey, Boston Consulting Group and Bain, which together account for almost half of the market. A lot of the people who work at Elixirr cut their teeth in this world, so they know what they’re up against. Newton was formerly a managing partner at Accenture, while chief financial officer Graham Busby worked in Accenture’s ‘global mega-deal’ department. The quality of the wider management team is also encouraging, with former BT chief executive Gavin Patterson acting as non-executive chair. The big question is whether Elixirr can keep luring talented people away from the corporate behemoths. The group has about 500 consultants but just 21 of them are client-facing partners. As partners generate the biggest invoices and bring in most of the work, swelling their ranks will be crucial for growth. In this sense, Elixirr has a lot in common with Keystone Law (KEYS), whose success relies on a team of 400 senior solicitors and which has seen recruitment slow down in recent months. However, while Keystone’s self-employed “principals&rd Management claims that partners can earn 80 per cent more at Elixirr than they could at a big rival firm because, while cash remuneration is lower, the money saved on pay packets is pumped back into the business, fuelling equity returns. “By investing £3.2mn in the business over five years and assuming 25 per cent compound annual growth rate (CAGR) share price growth, each partner can achieve an equity return of £7.2mn,” declares Elixirr, which loans new partners £500,000 to buy shares. It concludes that over a five-year period a partner can earn £9mn (including cash remuneration) compared with £5mn at a Big Four firm. Non-partners are also strongly equity incentivised via share options and an employee share purchase plan. On the one hand, this approach makes a lot of sense. One of the big conundrums posed by listed people businesses is how to align the interests of partners with those of external investors. Why would partners want to return profit to shareholders if they could distribute it all among themselves? Elixirr’s focus on equity means everyone is singing from the same hymn sheet. However, its logic falls apart if shares head south and partners watch their pay prospects wither. Share dilution is therefore something to watch for. Management stressed that the “value created from our equity incentive schemes far outweighs the potential dilutive effect” and analysts note that there has been no material dilution to the share count since April 2021. As the business keeps scaling up, however, it remains a risk. Growing pains Organic growth is not Elixirr’s only option, of course. It recently deployed some cash to acquire iOLAP, a US consultancy specialising in data and analytics. The deal makes strategic sense and is reminiscent of Alpha FMC’s Lionpoint purchase. Elixirr now has a sizable presence in the US, home to the world’s biggest consultancy market, and should benefit from plenty of cross-selling opportunities. It’s not easy to scale up a business at pace however, and Alpha FMC’s recent performance spotlights some of the problems that Elixirr could face. Fears about under-utilised consultants marred Alpha FMC’s latest annual results, where the group cited industry-wide “increased levels of competition as a result of overcapacity”. Its shares have fallen by 25 per cent since the start of the year after a bumper three-year period. Elixirr has a more varied client base than Alpha FMC, but it is not immune to market conditions. Staff costs as a percentage of revenues have risen over the past four years, and margins could suffer if work dries up. To make things worse, it is tricky to predict when or if a downturn is coming as contracts only last for four to eight weeks on average, limiting visibility and management’s capacity to plan. The firm’s resilience has been tested before, though: in 2020, the group achieved revenue growth of 24 per cent while the consulting market as a whole shrank by 18 per cent. Elixirr’s balance sheet is also reassuringly robust. The group has a net cash position, despite several acquisitions and dividend payments, and operations have proved reliably cash-generative so far: standard payment terms require settlement of invoices within 30 days of receipt, and the majority of trade receivables are less than 31 days old. Valuing potential Elixirr's share price has risen by 165 per cent since its IPO, so potential investors can be forgiven for feeling as though they’ve missed the boat. Small-cap valuations are slippery at the best of times, and the lack of publicly traded consultancies – together with a dearth of analyst coverage – makes valuing Elixirr even harder. However, there does appear to be a disconnect between its growth prospects and its price/earnings (PE) multiple. Analysis by Investec puts Elixirr on a PE ratio of 15.4 for the 2023 calendar year, despite a forecast sales CAGR for 2022-24 of 17 per cent. By contrast, Alpha FMC is expected to grow by 10 per cent but trades on a PE ratio of 18.1. Some will argue that Elixirr is cheap because it is small and risky. It has a short track record on the public market and is not widely covered by analysts. It is also exposed to partner and client exits, and its top three clients account for about a fifth of sales. On balance, however, the risk-reward balance looks enticing. As a capital-light sector challenger, Elixirr’s momentum could well persist for years to come. Taken together, profitable growth, a burgeoning client base and US expansion plans make for an intoxicating mixture. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
